ArticleClinical rheumatology2026
The clinical features, pathological findings, and risk factors of intracardiac thrombus in Behçet's syndrome.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesTo investigate the clinical features, pathological findings, and risk factors of intracardiac thrombus (ICT) in Behçet's syndrome (BS).
methodsWe conducted a case-control study using our BS registry database. BS patients with ICT were enrolled as the cases, and controls were selected using risk-set-sampling. Multivariable logistic regression identified risk factors, and outcomes were also analyzed. Pathology of six ICT specimens was reanalyzed by preoperative disease activity.
resultsSeventeen BS patients with ICT (14 males, 3 females, BS onset age: 26.4 ± 8.0 years) were enrolled. Compared to controls, ICT patients had higher venous involvement (70.6% vs. 13.7%, p < 0.001), pulmonary artery thrombosis (64.7% vs. 3.9%, p < 0.001), elevated ESR (26.0 vs. 9.8 mm/h, p = 0.013), CRP (34.7 vs. 10.1 mg/L, p < 0.001), and monocyte count (0.5 vs. 0.4*10^9/L, p = 0.024). Multivariable logistic regression identified CRP > 20 mg/L (OR 11.27, 95% CI 1.13-112.26, p = 0.039) and venous involvement (OR 11.71, 95% CI 2.79-49.20, p < 0.001) as ICT risk factors. Pathology revealed increased infiltration of neutrophils and CD68
conclusionICT in BS is a severe complication with a high relapse rate and pathological features of neutrophils and macrophages' infiltration. Elevated CRP (> 20 mg/L) and venous involvement are potential risk factors. These findings support the potential benefit of adequate immunosuppressive treatment before surgery for improving outcomes in BS patients with ICT. Key Points • ICT is a serious complication of BS, with a high relapse rate. • CRP > 20 mg/L and venous involvement are potential risk factors for ICT in BS. • Adequate immunosuppressive treatment before surgery is essential for improving outcomes in BS patients with ICT.
Indexed as
Identifiers
41329431What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.